TAK Takeda Pharmaceutical Company Limited
Healthcare$15.87-2.34%ClosedMarket Cap: $50.14B
As of 2026-05-26
Valuation
P/E (TTM)
80.98
PEG
—
P/B
1.01
P/S
1.77
EV/EBITDA
8.66
DCF Value
$37.61
FCF Yield
9.8%
Div Yield
4.0%
Margins & Returns
Gross Margin
58.8%
Operating Margin
10.5%
Net Margin
4.3%
ROE
2.6%
ROA
1.2%
ROIC
2.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 null | $1.11T | 48.8% | $47.54B | $-24.77B | $— | — |
| FY null | $4.78T | 51.1% | $573.04B | $203.33B | $— | $0.60 |
| Q3 null | $1.21T | 54.4% | $194.06B | $105.51B | $— | $0.32 |
| Q2 null | $1.11T | 65.8% | $69.00B | $-11.80B | $— | $0.32 |
| Q1 null | $1.11T | 65.2% | $184.57B | $124.24B | $— | $0.28 |
| Q4 null | $1.05T | 63.7% | $-74.90B | $-103.20B | $— | $0.28 |
| FY null | $4.58T | 65.5% | $342.59B | $107.93B | $— | $0.89 |
| Q3 null | $1.14T | 63.6% | $66.94B | $23.79B | $— | $0.33 |
| Q2 null | $1.18T | 66.5% | $184.25B | $92.05B | $— | $0.33 |
| Q1 null | $1.21T | 68.0% | $166.33B | $95.25B | $— | $0.29 |
| Q4 null | $1.05T | 63.1% | $-10.07B | $-3.02B | $— | $0.29 |
| FY null | $4.26T | 66.4% | $214.07B | $144.07B | $— | $0.92 |